Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR10624 Added to Icosapent Ethyl in Severe Hypertriglyceridemia
NCT07680829Phase 3Not yet recruiting
- Sponsor
- Doer Bio
- Start
- Aug 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of DR10624 in hypertriglyceridemia (3 arms), sponsored by Doer Bio. Primary endpoint: Percentage change from baseline in average fasting serum triglyceride concentration at 26 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
DR10624
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT07680829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07680829.